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PcG and TrxG proteins mostly with opposite transcriptional activities play key roles in normal and malignant
development. In this issue of Cancer Cell, Tan et al. report an unexpected collaboration between CBX8 and
MLL-AF9 in leukemia, revealing a farmore complicated functional crosstalk between thesemaster epigenetic
regulators in oncogenesis.Leukemia patients carrying chimeric
fusion of the mixed lineage leukemia
(MLL) gene remain one of the worst prog-
nostic subgroups with poor remission
andhigh relapse rates.MLL is themamma-
lian homolog of Trithorax, the founding
member of trithorax group (TrxG) proteins,
which function antagonistically with poly-
comb group (PcG) proteins to regulate ex-
pression of critical developmental genes
such as HOX (Figure 1A). Consistently,
HOX genes are aberrantly activated in
MLL, and suppression of HOXA9 partially
compromises MLL fusion-mediated
transformation (Cheung and So, 2011).
Biochemical purifications of protein
complexes associated with MLL fusions
discovered critical epigenetic modifying
enzymes including DOT1L (Okada et al.,
2005) and PRMT1 (Cheung et al., 2007)
that mediate methylation of specific resi-
dues on histones for transcriptional activa-
tion. Inhibition of these histone-modifying
enzymes suppresses HOX expression
and cellular transformation by MLL
fusions, confirming the aberrant recruit-
ment of transactivation complexes as
a major attribute to MLL leukemogenesis.
Unexpectedly, chromobox 8 (CBX8),
a PcG protein, was also recurrently identi-
fied as an interacting protein with MLL
fusion partners, AF9 and ENL, in spite of
its putative function in transcriptional
repression (Garcı´a-Cue´llar et al., 2001;
Monroe et al., 2010). The significance of
this interaction and its role in MLL leuke-
mogenesis are largely unknown.
PcG Protein, CBX8, As an Essential
Component and Potential Target for
MLL Leukemia
In this issue of Cancer Cell, Tan et al.
(2011) have performed extensive bio-chemical and cell biology studies to
characterize the role of CBX8 in MLL
leukemia. First, they identified two
highly-specific AF9 point mutants
(T542A and T554A) that preferentially
lost their interaction with CBX8 but not
with DOT1L, AF5q31, or p-TEFb complex.
Interestingly, these MLL-AF9 mutants
failed to transform primary hematopoietic
cells in spite of maintaining their interac-
tion with DOT1L and p-TEFb complex.
To further demonstrate the specific
requirement of CBX8 in MLL leukemia,
mouse bone marrow cells carrying Cbx8
floxed/conditional alleles were employed
together with wild-type MLL-AF9 in the
transformation assays. MLL-AF9 was
capable of transforming Cbx8 floxed cells
and induced leukemia in mice. However,
an acute homozygous deletion of Cbx8
in the first or third round of plating almost
completely abolished the transformation
ability and leukemogenic potential by
MLL-AF9 but not E2A-HLF, confirming
a specific functional requirement of
CBX8 for MLL leukemogenesis.
To gain further insights into the molec-
ular functions of CBX8 in MLL leukemia,
the authors demonstrated that shRNA
mediated suppression of CBX8 but not
other core components of polycomb
repressive complex 1 (PRC1), such as
RING1b and BMI1, significantly reduced
the expression of HOXA9 and compro-
mised MLL-AF9 transformation ability.
These data suggest that the CBX8
requirement may not be directly related
to the classical PRC1 function, but rather
its ability to help maintain expression of
MLL-AF9 downstream targets. In spite of
its well-characterized repression prop-
erty, CBX8 is also known to interact with
TIP60, which possesses histone-acetyl-Cancer Cell 20, Ntransferase activity, which may explain
the transactivation function of Cbx8.
Consistently, suppression of TIP60 ex-
pression by shRNAs inhibited expression
ofHOXA9- andMLL-AF9-mediated trans-
formation in vitro, suggesting a functional
link between CBX8 and TIP60 in MLL
leukemia. Finally, the authors further
showed that CBX8 was not required for
development of normal murine hemato-
poietic stem cells, highlighting it as
a potential therapeutic target.
It is interesting to note that although
CBX8, in contrast to DOT1L and PRMT1,
does not contain rigid enzymatic struc-
turesas ideal docking-sites for smallmole-
cule inhibitors, a recent study shows that
inhibitors can be developed to success-
fully target acetyl-lysine recognizing
domain in the BET family for suppression
of MLL leukemia (Dawson et al., 2011).
Thus, the chromodomain of Cbx8 may
also be a traceable target for inhibitor
development if it is, indeed, required for
MLL leukemia. On the other hand, the
well-structured aceyltransferase domain
in TIP60 could also be a good target,
although its role in MLL leukemic transfor-
mation is far less clear and its functional
involvement in multiple essential cellular
processes also dampers the enthusiasm.
An Emerging Paradigm for
Collaboration between PcG
Proteins and MLL Fusions
in Leukemia
In addition to the potential therapeutic
implication, this study also highlights an
interesting biological question and recent
challenge in understanding the functional
relationship between PcG and TrxG
proteins in cancer. In solid tumors, TrxG
proteins such as SNF5, BRM, and BRG1ovember 15, 2011 ª2011 Elsevier Inc. 551
Figure 1. Functional Crosstalk between PcG and
TrxG Proteins in Normal and Malignant Development
(A) PcG and TrxG proteins with opposite transcriptional activ-
ities coregulate the expression of PcG targets to maintain
transcription programs for normal development.
(B) Chromatin remodelling TrxG proteins such as SNF5
function as tumor suppressors against PcG/EZH2 proteins
by activating the expression of PcG targets.
(C) Histone modifying TrxG proteins such as MLL may collab-
orate with PcG proteins to (1) activate HOX gene expression
and (2) suppress expression of INK4A/ARF loci for leukemo-
genic transformation.
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Previewsmay act as tumor suppressors to
counteract the oncogenic functions
of PcG proteins, such as EZH2 and
BMI1, which are frequently
activated in various cancers (Fig-
ure 1B). However, a recent study
has shown that BMI1 collaborates
with MLL fusion for the development
of leukemic stem cells (Smith et al.,
2011). BMI1, as a major gatekeeper
for cellular senescence, is required
for transformation mediated by a
number of leukemia associated
transcription factors. Nonetheless,
MLL fusion-mediated activation of
Hox expression can compensate for
the lack ofBmi1, in part by suppress-
ing Ink4a/Arf expression. Consis-
tently, forced expression of Hoxa9
can also suppress cellular senes-
cence induced by BMI1-dependent
leukemia-associated transcription
factors such as AML1-ETO and
PLZF-RARa in the absence of Bmi1
(Smith et al., 2011). In contrast to
the classical antagonistic relation-
ship, BMI1 and MLL/HOX may actu-
ally cooperate to suppress the major
checkpoint guarded by Cdkn2a/2b
loci to promote oncogenic transfor-
mation (Figure 1C). The current
study by Tan et al. (2011) further rein-
forces this idea by making a direct
biochemical link between PcG and
MLL fusion proteins where CBX8
forms a part of the MLL fusion tran-
scriptional complex to help activate
expression of downstream targets
such as HOX genes (Figure 1C).
In contrast to BMI1, the CBX8-
mediated transactivation of HOX
by MLL fusions seems to be inde-
pendent of the normal PRC1 func-
tions, because specific knockdown
of other PRC1 components did not
have any significant effect on HOX
gene expression or transformation
byMLL-AF9. This suggests the pres-
ence of multiple intersecting points
between MLL fusions and different
members of PcG proteins in medi-
ating acute leukemogenesis. So far,
these two studies focus on compo-
nents of PRC1. It is very possible
that members of PRC2 such as
EZH2, which is mutated in myeloid
malignancies (Ernst et al., 2010;
Nikoloski et al., 2010), may also be
interacting with TrxG proteins for552 Cancer Cell 20, November 15, 2011 ª2011 Elsevier Inc.leukemogenesis. Another major
outstanding question is: what are
the factors that determine if PcG
proteins should cooperate or antag-
onize with TrxG proteins for onco-
genic transformation (Figure 1)? It is
clear that tissue specific transcrip-
tion factors and interacting cofac-
tors, which respectively dictate the
DNA binding specificity and com-
position of the transcriptional com-
plexes associated with PcG/TrxG
proteins, can play a key role in deter-
mining the nature and outcome of
their functional interactions. On the
other hand, TrxG proteins consist of
a diverse group of proteins with
different molecular functions. In con-
trast to MLL protein with histone-
modification property, TrxG proteins
such as SNF5 directly associated
with nucleosome-remodelling ac-
tivity act in an antagonistic way
against the oncogenic function of
PRC in solid tumors (Wilson et al.,
2010). However, this has not been
investigated in leukemia, which has
a totally different set of tissue
specific transcription factors and
interactomes. Thus future studies
examining the functional interaction
between different classes of TrxG
and PcG proteins will give unique
insights into this important issue.
Nevertheless, these recent studies
reveal a far more complicated
crosstalk between PcG and TrxG
proteins in oncogenesis, and func-
tional cooperation between these
proteins emerges as a new theme
in leukemogenesis.
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Metastasis of epithelial tumors critically depends on acquisition of a disseminating phenotype that allows
tumor cells to colonize distant organs. In this issue of Cancer Cell, Labelle et al. demonstrate that an epithe-
lial-mesenchymal-like transition can be induced by interaction between platelets and tumor cells.Host cell types provide cues that regulate
tumor metastasis, essentially at all stages
of tumor progression. Cells disseminating
from primary epithelial tumors use the
bloodstream and lymphatics to colonize
distant sites. The impact of tumor-host
interactions encountered within the
bloodstream has been explored far less
than that occurring in primary tumors
and distant lesions. There are primarily
three reasons: microenvironments within
the vasculature are difficult to access,
hard to define, and transient in nature.
While cancer patients often present with
conditions indicating activation of plate-
lets and the coagulation system, the role
of platelets in cancer dissemination is
only partially understood (Erpenbeck and
Scho¨n, 2010; Gay and Felding-Haber-
mann, 2011). In this issue of Cancer Cell,
Labelle et al. (2011) demonstrate a novel
role for platelets that profoundly impacts
the ability of blood borne tumor cells to
seed distant metastases. Direct platelet
signaling to tumor cells leads to en-
hanced metastasis through platelet re-
lease of transforming growth factor b
(TGF-b) which induces epithelial-mesen-chymal-like transition in tumor cells and
is critically enhanced through direct
tumor cell-platelet contact.
Platelets are key contributors to he-
mostasis, leukocyte trafficking during
inflammation, and maintenance of vessel
stability. A hallmark of platelet function
is the prevention of hemorrhage and
perpetuation of coagulation to form and
stabilize blood clots. Platelets are impli-
cated in supporting metastasis through
coherence with tumor cells, formation
of heteroaggregates that also include
leukocytes (La¨ubli et al., 2006), and pro-
teins of the coagulation system that pro-
vide a transient microenvironment, which
supports tumor cell survival and protec-
tion from immune elimination (Palumbo
et al., 2005).
As the links between platelets, coagula-
tion, and tumor metastasis coalesce,
platelet-specific factors and recipient sig-
naling mechanisms on tumor cells, im-
portant for malignancy, are still being
resolved in mouse models. Labelle et al.
(2011) now identify specific platelet factor
and signaling pathways evoked in tumor
cells that critically support metastasis.By conditioning tumor cells with platelets
in vitro, the authors elicit colon and breast
carcinoma cells to become more invasive
and mesenchymal-like and ultimately
more aggressive in an experimental lung
metastasis model. This enhanced me-
tastasis shows that the initial exposure
to platelets can reprogram tumor cells.
Thus, these results extend beyond docu-
mented contributions of platelets to tumor
cell arrest, survival, and immune evasion
en route tometastasis (Figure 1). Signaling
factors released from platelet granules
could directly affect tumor cell survival,
proliferation, or invasiveness during me-
tastasis. In a definitive and beautifully-
executed experiment, Labelle et al.
(2011) knockout expression of TGF-b1
specifically in megakaryocytes, and
hence in platelets, by generating a
TGF-b1 floxed/platelet factor 4 cremouse
model (Pf4-cre+; TGFb1fl/fl). The dramati-
cally diminished metastasis seen in mice
deficient in platelet TGF-b1 suggests that
tumor cell behavior is altered as a result
of platelet activation and release of alpha
granules. A lack of TGF-b1 in platelets
also delayed tumor cell extravasation inovember 15, 2011 ª2011 Elsevier Inc. 553
